Details for Patent: 9,045,487

Which drugs does patent 9,045,487 protect, and when does it expire?

Patent 9,045,487 protects RUBRACA and is included in one NDA.

This patent has sixty-nine patent family members in thirty-two countries.

Summary for Patent: 9,045,487

Title:	Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
Abstract:	The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.
Inventor(s):	Patricia Ann Basford, Anthony Michael Campeta, Adam Gillmore, Matthew Cameron Jones, Eleftherios Kougoulos, Suman Luthra, Robert Walton
Assignee:	Pfizer Corp SRL
Application Number:	US14/272,589
Patent Claim Types: see list of patent claims	Composition; Compound;

error: insufficient information

Drugs Protected by US Patent 9,045,487

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pharmaand	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-001	Dec 19, 2016		RX	Yes	No			Y	Y
Pharmaand	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-003	May 1, 2017		RX	Yes	No			Y	Y
Pharmaand	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-002	Dec 19, 2016		RX	Yes	Yes			Y	Y

International Family Members for US Patent 9,045,487

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2534153		300958	Netherlands
European Patent Office	2534153		CA 2018 00041	Denmark
European Patent Office	2534153		122018000131	Germany